[{"id":"626de316-d799-4804-9309-0166aa718911","acronym":"NCI-2018-01296","url":"https://clinicaltrials.gov/study/NCT02983578","created_at":"2021-01-18T14:40:40.387Z","updated_at":"2025-02-25T15:07:25.564Z","phase":"Phase 2","brief_title":"Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer","source_id_and_acronym":"NCT02983578 - NCI-2018-01296","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • STAT3","pipe":" | ","alterations":" PD-L1 expression • STAT3 expression","tags":["CD8 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • STAT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/02/2017","start_date":" 03/02/2017","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-08-27"},{"id":"49dcbbff-6ced-48b8-82ea-1df1dba75ce8","acronym":"BAZE","url":"https://clinicaltrials.gov/study/NCT04812808","created_at":"2021-03-24T16:10:47.311Z","updated_at":"2024-07-02T16:36:16.409Z","phase":"","brief_title":"Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04812808 - BAZE","lead_sponsor":"Hôpital Fribourgeois","biomarkers":" IL6 • STAT3","pipe":" | ","alterations":" STAT3 expression • IL6 expression","tags":["IL6 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 expression • IL6 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2022-02-25"},{"id":"f3d6b05f-3b8f-4428-a7d4-82d5031c9793","acronym":"","url":"https://clinicaltrials.gov/study/NCT01568996","created_at":"2021-01-18T06:39:24.188Z","updated_at":"2024-07-02T16:37:14.979Z","phase":"Phase 1","brief_title":"Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions","source_id_and_acronym":"NCT01568996","lead_sponsor":"John Kirkwood","biomarkers":" ALK • STAT3","pipe":" | ","alterations":" STAT3 expression","tags":["ALK • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 expression"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2018-01-09"}]